Olin J J
University of Vermont College of Medicine, Burlington, Vermont, USA.
Oncology (Williston Park). 2001 May;15(5):613-8; discussion 618, 621-4.
An underinvestigated area of breast cancer survivorship involves the possible impairment of cognitive function following adjuvant chemohormonal therapy. Numerous reports of disturbing and disruptive changes in short- and long-term memory, attention span, concentration, and language skills have been made by breast cancer patients who have received chemotherapy. This article reviews the four published studies that have documented cognitive dysfunction following adjuvant chemohormonal therapies commonly used in breast cancer. The studies describe a subset of approximately one-third of participants who experienced long-term cognitive impairment. Patient- and treatment-related factors that may influence cognitive function are outlined. The impact of these cognitive impairments on the individual breast cancer survivor's quality of life is discussed, as is the potential overall impact of this research on future adjuvant therapy. The need for a prospective longitudinal study documenting the neuropsychological sequelae of adjuvant chemohormonal therapy is emphasized.
乳腺癌幸存者中一个未得到充分研究的领域涉及辅助化学激素治疗后可能出现的认知功能损害。接受化疗的乳腺癌患者报告了许多关于短期和长期记忆、注意力持续时间、专注力及语言技能方面令人不安和具有破坏性变化的情况。本文回顾了四项已发表的研究，这些研究记录了乳腺癌常用辅助化学激素治疗后出现的认知功能障碍。研究描述了约三分之一的参与者经历长期认知损害的情况。概述了可能影响认知功能的患者及治疗相关因素。讨论了这些认知损害对个体乳腺癌幸存者生活质量的影响，以及该研究对未来辅助治疗的潜在总体影响。强调了开展一项前瞻性纵向研究以记录辅助化学激素治疗神经心理学后遗症的必要性。
